Clinical trials: Chronic (Non-malignant) Musculoskeletal Pain

Chronic Pain

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects

• Withdrawn
• Age: 2 to 6 years
• Phase 3

The purpose of this study is to evaluate the effectiveness, tolerability, and safety of oxymorphone immediate release (IR) oral liquid as an analgesic in pediatric subjects having severe to moderate chronic pain.

Trial name

NCT01206907

Testing

oxymorphone IR

Sponsor

Endo USA Inc., a Keenova Therapeutics Company